These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 32609446)

  • 21. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
    Craiglow BG; King BA
    JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of tofacitinib in IBD: A tricky puzzle.
    Beaugerie L
    United European Gastroenterol J; 2024 Jul; 12(6):658-659. PubMed ID: 38761370
    [No Abstract]   [Full Text] [Related]  

  • 23. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
    Mamolo C; Harness J; Tan H; Menter A
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):192-203. PubMed ID: 23294276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
    Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Janus kinase inhibitor tofacitinib inhibits TNF-α-induced gliostatin expression in rheumatoid fibroblast-like synoviocytes.
    Kawaguchi Y; Waguri-Nagaya Y; Tatematsu N; Oguri Y; Kobayashi M; Nozaki M; Asai K; Aoyama M; Otsuka T
    Clin Exp Rheumatol; 2018; 36(4):559-567. PubMed ID: 29352846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
    Gupta AK; Cernea M; Lynde CW
    Skin Therapy Lett; 2017 Mar; 22(2):1-7. PubMed ID: 28329404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis.
    Ma G; Xie R; Strober B; Langley R; Ito K; Krishnaswami S; Wolk R; Valdez H; Rottinghaus S; Tallman A; Gupta P
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):587-596. PubMed ID: 29856518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.
    King B; Lee AI; Choi J
    J Invest Dermatol; 2017 Apr; 137(4):951-954. PubMed ID: 27887955
    [No Abstract]   [Full Text] [Related]  

  • 30. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
    Yamaoka K; Tanaka Y
    Expert Opin Pharmacother; 2014 Jan; 15(1):103-13. PubMed ID: 24188100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.
    Desai RJ; Pawar A; Weinblatt ME; Kim SC
    Arthritis Rheumatol; 2019 Jun; 71(6):892-900. PubMed ID: 30552833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
    Yiu ZZ; Warren RB
    Am J Clin Dermatol; 2016 Jun; 17(3):191-200. PubMed ID: 26923915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful treatment of refractory palmoplantar psoriasis in a psoriatic arthritis patient with the JAK inhibitor tofacitinib.
    Valor-Méndez L; Sticherling M; Kleyer A; Schett G
    Clin Exp Rheumatol; 2021; 39(1):228. PubMed ID: 32828149
    [No Abstract]   [Full Text] [Related]  

  • 34. Pulmonary Cryptococcosis in the Setting of Tofacitinib Therapy for Psoriasis.
    Seminario-Vidal L; Cantrell W; Elewski BE
    J Drugs Dermatol; 2015 Aug; 14(8):901-2. PubMed ID: 26267737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [JAK inhibitor].
    Yamaoka K; Tanaka Y
    Nihon Rinsho; 2013 Jul; 71(7):1243-7. PubMed ID: 23961674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The emerging safety profile of JAK inhibitors in rheumatic disease.
    Winthrop KL
    Nat Rev Rheumatol; 2017 Apr; 13(4):234-243. PubMed ID: 28250461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
    De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
    J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
    Curtis JR; Zhang R; Krishnaswami S; Anisfeld A; Chen Y; Strengholt S; Chen C; Geier J
    Clin Rheumatol; 2017 Mar; 36(3):683-688. PubMed ID: 27470086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Full Guidelines-From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis.
    James WA; Rosenberg AL; Wu JJ; Hsu S; Armstrong A; Wallace EB; Lee LW; Merola J; Schwartzman S; Gladman D; Liu C; Koo J; Hawkes JE; Reddy S; Prussick R; Yamauchi P; Lewitt M; Soung J; Weinberg J; Lebwohl M; Glick B; Kircik L; Desai S; Feldman SR; Zaino ML
    J Am Acad Dermatol; 2024 Aug; 91(2):251.e1-251.e11. PubMed ID: 38499181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral small molecules for psoriasis.
    Singh S; Armstrong AW
    Semin Cutan Med Surg; 2018 Sep; 37(3):163-166. PubMed ID: 30215633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.